Prognostic impact of histological subtyping in triple-negative breast cancer

被引:0
|
作者
Grosse, Claudia [1 ]
Noack, Petar [1 ]
Grosse, Alexandra [2 ]
Preuss, Caroline Ines [3 ]
Schwarz, Heike Kathleen [4 ]
Gitter, Thomas [5 ]
Schrenk, Peter [6 ]
Frauchiger-Heuer, Heike [7 ,8 ]
Papassotiropoulos, Barbel [9 ]
Tausch, Christoph [9 ]
Maccio, Umberto [10 ]
Moch, Holger [10 ]
Langer, Rupert [1 ]
Varga, Zsuzsanna [8 ,10 ]
机构
[1] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Pathol & Mol Pathol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[2] Pathol Inst Enge, Hardturmstr 133, CH-8005 Zurich, Switzerland
[3] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Gynecol Obstet & Gynecol Endocrinol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[4] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Hematol & Oncol, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[5] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Cent Radiol Inst, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[6] Johannes Kepler Univ Linz, Kepler Univ Hosp GmbH, Dept Gen & Visceral Surg, Altenberger Str 69 & Krankenhausstr 9, A-4040 Linz, Austria
[7] Univ Hosp Zurich, Clin Gynecol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
[8] Univ Hosp Zurich, Comprehens Breast Canc Ctr, Zurich, Switzerland
[9] Breast Ctr Seefeld, Seefeldstr 214, CH-8008 Zurich, Switzerland
[10] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
关键词
Breast cancer; Triple-negative phenotype; special histological types; Prognostic stratification; Therapy response; CLINICOPATHOLOGICAL FEATURES; METAPLASTIC CARCINOMA; SURVIVAL OUTCOMES; HETEROGENEITY; DISEASE; SUBSET;
D O I
10.1016/j.humpath.2024.105640
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (P G 0.001) and had a lower Ki67 index (P G 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (P = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (P G 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, P = 0.002; DDFS, P = 0.001) and in the non-NAC subgroup (OS, P = 0.034; DFS, P = 0.001; DDFS, P G 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with highgrade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, P = 0.049; DFS, P G 0.001; DDFS, P = 0.001; non-NAC subgroup: OS, P = 0.014; DFS, P G 0.001; DDFS, P G 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Pharmacotherapy of triple-negative breast cancer
    Arslan, Cagatay
    Dizdar, Omer
    Altundag, Kadri
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (13) : 2081 - 2093
  • [22] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [23] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [24] Immunotherapy in triple-negative breast cancer
    Heather Katz
    Mohamed Alsharedi
    Medical Oncology, 2018, 35
  • [25] Inflammatory response-based subtyping and potential therapeutic strategies for triple-negative breast cancer
    Li, Ze-Qing
    Zhang, Wen-Juan
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    Ma, Ding
    Wu, Jiong
    REPRODUCTIVE AND DEVELOPMENTAL MEDICINE, 2023, 7 (03) : 156 - 165
  • [26] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [27] Alarming Burden of Triple-Negative Breast Cancer in India
    Thakur, Krishan K.
    Bordoloi, Devivasha
    Kunnumakkara, Ajaikumar B.
    CLINICAL BREAST CANCER, 2018, 18 (03) : E393 - E399
  • [28] Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker
    O'Conor, Christopher J.
    Chen, Tiffany
    Gonzalez, Ivan
    Cao, Dengfeng
    Peng, Yan
    BIOMARKERS IN MEDICINE, 2018, 12 (07) : 813 - 820
  • [29] Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin
    Hu, H.
    Tong, K.
    Tsang, J. Y.
    Ko, C. W.
    Tam, F.
    Loong, T. C.
    Tse, G. M.
    ESMO OPEN, 2024, 9 (04)
  • [30] Development of an immune-related prognostic biomarker for triple-negative breast cancer
    Zhang, Yan
    Wang, Quan
    Yang, Wei-Kang
    Wang, Yong-Si
    Zhou, Qiao
    Lin, Jie
    Wei, Xu-Xuan
    Liang, Tian
    Liu, Tongtong
    Fan, Wen-Tao
    Liang, Li
    Xu, You-Nian
    ANNALS OF MEDICINE, 2022, 54 (01) : 1212 - 1220